DK1802749T3 - KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser - Google Patents

KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser

Info

Publication number
DK1802749T3
DK1802749T3 DK05797320.8T DK05797320T DK1802749T3 DK 1802749 T3 DK1802749 T3 DK 1802749T3 DK 05797320 T DK05797320 T DK 05797320T DK 1802749 T3 DK1802749 T3 DK 1802749T3
Authority
DK
Denmark
Prior art keywords
kaspp
lrrk2
gene
preparation
detection
Prior art date
Application number
DK05797320.8T
Other languages
English (en)
Inventor
Thomas Meitinger
Tim Matthias Strom
Marius Ueffing
Elisabeth Kremmer
Thomas Gasser
Petra Leitner
Friedrich Asmus
Nadja Patenge
Alexander Zimprich
Matthew J Farrer
Jennifer M Kachergus
Sara J Lincoln
Mary M Hulihan
Zibigniew Wszolek
Ryan Uitti
Saskia Biskup
Christian J Gloeckner
Original Assignee
Mayo Foundation
Helmholtz Zentrum Muenchen
Univ Eberhard Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation, Helmholtz Zentrum Muenchen, Univ Eberhard Karls filed Critical Mayo Foundation
Application granted granted Critical
Publication of DK1802749T3 publication Critical patent/DK1802749T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DK05797320.8T 2004-10-21 2005-09-27 KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser DK1802749T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62089304P 2004-10-21 2004-10-21
US62116904P 2004-10-22 2004-10-22
PCT/EP2005/010428 WO2006045392A2 (en) 2004-10-21 2005-09-27 Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
DK1802749T3 true DK1802749T3 (da) 2012-11-26

Family

ID=35965998

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05797320.8T DK1802749T3 (da) 2004-10-21 2005-09-27 KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser

Country Status (7)

Country Link
US (2) US8029986B2 (da)
EP (2) EP2316927B1 (da)
AU (1) AU2005299089B2 (da)
CA (1) CA2584489C (da)
DK (1) DK1802749T3 (da)
ES (1) ES2393926T3 (da)
WO (1) WO2006045392A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
AU2007261095A1 (en) * 2006-06-20 2007-12-27 Novartis Ag Biomarkers for the progression of Alzheimer's disease
US8206942B2 (en) * 2007-04-05 2012-06-26 Medical Research Council Methods of identifying LRRK2 inhibitors
US20100186098A1 (en) * 2007-06-27 2010-07-22 Cornell University Transgenic animal models of parkinson's disease
US9267151B2 (en) * 2008-08-20 2016-02-23 Brainco Biopharma, S.L. STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness
US20100175140A1 (en) * 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
ES2524892T3 (es) 2010-09-02 2014-12-15 Glaxosmithkline Intellectual Property Development Limited 2-(Benciloxi)benzamidas como inhibidores de LRRK2 quinasa
JP6082397B2 (ja) 2011-09-30 2017-02-15 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． マクロ環状ｌｒｒｋ２キナーゼ阻害剤
EP3255049A1 (en) 2012-06-29 2017-12-13 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
EA029774B1 (ru) 2014-01-29 2018-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
US10058559B2 (en) 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
US10004751B2 (en) 2014-07-10 2018-06-26 The J. David Gladstone Institutes Compositions and methods for treating Dengue virus infection
PL3194405T3 (pl) 2014-09-17 2019-07-31 Oncodesign S.A. Makrocykliczne inhibitory kinazy lrrk2
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
US10907160B2 (en) 2016-01-05 2021-02-02 Ionis Pharmaceuticals, Inc. Methods for reducing LRRK2 expression
CA3069554A1 (en) 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
AU7345694A (en) 1993-07-10 1995-02-06 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
AU726501B2 (en) 1996-06-04 2000-11-09 University Of Utah Research Foundation Monitoring hybridization during PCR
AU2002327419A1 (en) * 2001-08-02 2003-02-17 Incyte Genomics, Inc. Kinases and phosphatases
WO2003101283A2 (en) * 2002-06-04 2003-12-11 Incyte Corporation Diagnostics markers for lung cancer
WO2004006838A2 (en) * 2002-07-15 2004-01-22 Sugen, Inc. Novel kinases
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics

Also Published As

Publication number Publication date
EP2316927A2 (en) 2011-05-04
CA2584489A1 (en) 2006-05-04
AU2005299089B2 (en) 2011-08-18
EP2316927A3 (en) 2011-10-19
WO2006045392A3 (en) 2006-08-10
ES2393926T3 (es) 2013-01-02
US8029986B2 (en) 2011-10-04
US20120035072A1 (en) 2012-02-09
US8409809B2 (en) 2013-04-02
EP1802749B1 (en) 2012-08-22
CA2584489C (en) 2014-07-22
EP2316927B1 (en) 2014-11-05
US20100235933A1 (en) 2010-09-16
AU2005299089A1 (en) 2006-05-04
EP1802749A2 (en) 2007-07-04
WO2006045392A2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
DK1802749T3 (da) KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1812110T3 (da) Apparat til behandling af dermatologiske lidelser
DK2878297T3 (da) Lægemidler til behandling og forebyggelse af fibrotiske sygdomme
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK1888294T3 (da) Fremgangsmåde til hårdlodning af artikler af rustfrit stål
DK2617714T3 (da) Kemiske derivater af jasmonat, farmaceutiske præparater og fremgangsmåder til anvendelse deraf
DK2120604T3 (da) Fremgangsmåde til fraktionering af havre, produkter derved opnået, og anvendelser deraf
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK2109602T3 (da) Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner
DK1740197T3 (da) Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki
DK2044076T3 (da) Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK2057153T3 (da) (3-aryl-piperazin-1-yl)-derivater af 6,7 dialkoxyquinazolin, 6,7- dialkoxyphtalazin og 6,7-dialkoxyisoquinolin
DK1765355T3 (da) Benzoxazin til behandling af luftvejslidelser
DK1916995T4 (da) Ph-styret, pulserende indgivelsessystem, fremgangsmåder til fremstilling og anvendelse deraf
DK1848415T3 (da) Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose
DK1919909T3 (da) Syntesemetoder og mellemprodukter for stereoisomere forbindelser, der er anvendelige til behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet